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Introduction: Travoprost 0.004%/timolol maleate 0.5% fixed combination eye drops are 
  available in Japan. We prospectively investigated the intraocular pressure (IOP)-decreasing effect 
of travoprost 0.004%/timolol maleate 0.5% fixed combination eye drops and the   adherence of 
patients to the administration protocol.
Materials and methods: We studied 43 eyes from 43 patients diagnosed with primary 
  open-angle glaucoma, who were using prostaglandin analogs and β-blockers. The   prostaglandin 
analogs and β-blockers were discontinued, and the treatment regimen was changed to   travoprost 
0.004%/timolol maleate 0.5% fixed combination eye drops without any washout period. IOP 
before and at 1 month, 3 months, and 6 months after the treatment change was evaluated and 
compared. A questionnaire about protocol adherence was administered 1 month after the 
  treatment change.
Results: IOP was 15.7 ± 2.9 mmHg before the change, 15.5 ± 2.7 mmHg at 1 month after the 
change, 15.3 ± 3.6 mmHg at 3 months after the change, and 15.8 ± 3.2 mmHg at 6 months 
after the change, and none of the differences were significant (P = 0.191). The responses to the 
questionnaire showed that cases where eye drop administration was forgotten decreased after the 
treatment change. Moreover, because of changes in eye drops, 19.0% of patients had irritation. 
More than half (54.8%) of the patients preferred travoprost 0.004%/timolol maleate 0.5% fixed 
combination eye drops. Seven patients (16.3%) discontinued eye drop use because of adverse 
reactions within 6 months after the change.
Conclusion: When the treatment regimen was changed from prostaglandin analogs 
and β-blockers to travoprost 0.004%/timolol maleate 0.5% fixed combination eye drops, 
  administration protocol adherence increased and IOP was preserved; however, adverse reactions 
appeared in about 16% of the cases.
Keywords: travoprost 0.004%/timolol maleate 0.5% fixed combination, β-blockers, 
  prostaglandin analog, change, intraocular pressure
Introduction
Prostaglandin analogs are the primary treatment for glaucoma in recent years because of 
their strong intraocular pressure (IOP)-lowering efficacy, safety (because of few systemic 
adverse reactions), and convenience of once-a-day treatment. However, in cases where 
prostaglandin treatment does not sufficiently lower IOP, management is modified or 
additional administration of other eye drops is initiated. When this   process is repeated, 
patients soon become multidrug cases, and poor protocol   adherence becomes a   problem.1 
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In order to improve adherence to treatment protocols, 
  combination eye drops were developed. In Japan, travoprost 
0.004%/timolol maleate 0.5% fixed combination eye drops 
(DuoTrav Combination Ophthalmic Solution; Alcon Japan 
Ltd, Tokyo, Japan) became available in June 2010. When 
patients who were concomitantly using prostaglandin ana-
logs and β-blockers switched to travoprost 0.004%/timolol 
maleate 0.5% fixed combination eye drops, there were expec-
tations of lessening of administration frequency, increase in 
protocol adherence, and decreases in IOP. Some studies have 
reported a hypotensive effect when therapy is changed from 
prostaglandin analogs and β-blockers to travoprost 0.004%/
timolol maleate 0.5% fixed combination eye drops.2–5 These 
studies show that IOP was similar2 or that IOP significantly 
decreased3–5 with the new treatment protocol, but no studies 
have included Japanese patients as subjects.
The purpose of this study was to evaluate the safety, 
adherence to administration protocol, and reduction in 
IOP when treatment is switched from concomitant use of 
prostaglandin analogs and β-blockers to travoprost 0.004%/
timolol maleate 0.5% fixed combination eye drops in patients 
diagnosed with primary open-angle glaucoma (POAG).
Materials and methods
This prospective study was conducted at the Inouye Eye 
  Hospital from May 2010 to June 2011 and included 43 eyes 
from 43 patients (men: 23 patients, 23 eyes; women: 
20 patients, 20 eyes) diagnosed with POAG (including 
normal tension glaucoma) and concomitantly using prosta-
glandin analogs and β-blockers. The mean patient age was 
67.6 ± 11.1 years (mean age ± standard deviation) (range 
40–86 years). In terms of disease type, ten cases were normal 
tension glaucoma and 33 cases were POAG. In terms of the 
number of glaucoma medications formerly used by patients, 
25 patients had been using two medications, eleven patients 
used three medications, and seven patients used four medi-
cations. Among prostaglandin analogs, travoprost was used 
by 23 patients, latanoprost by 15 patients, tafluprost by four 
patients, and isopropyl unoprostone by one patient. β-blockers 
were used in conjunction with timolol in 29 cases, carteolol 
in eleven cases, levobunolol in two cases, and nipradilol 
in one case. Mean deviation by the Humphrey visual field 
test before the change was −9.42 ± 7.24 dB (range −24.01 
to 0.41 dB). IOP before the change was 15.7 ± 2.9 mmHg 
(range 8–24 mmHg). If both eyes met the inclusion criteria, 
the eye with the higher IOP was selected. If both eyes had the 
same IOP, the right eye was selected. In a monocular case, 
the corresponding eye was selected for analysis.
Prostaglandin analogs and β-blockers were discontinued 
without any washout period, and treatment was changed to 
travoprost 0.004%/timolol maleate 0.5% fixed combination eye 
drops (once a day, at night). Other eye drops were continued. 
The IOP before and at 1 month, 3 months, and 6 months after 
the switch was measured and compared by analysis of variance 
(ANOVA) and the Bonferroni/Dunnet test. IOP was measured 
by the same examiner at approximately the same time with a 
Goldmann applanation tonometer (Haag-Streit AG, Koeniz, 
Switzerland). A self-registering questionnaire about protocol 
adherence was conducted 1 month after the change (Chi-square 
test). The questionnaire included six questions:
1.  How often does it happen that you forget to administer 
eye drops (before and after the change)?
2.  Compared to before the change, did it sting when admin-
istering the current eye drops?
(1) stings (2) same (3) does not sting
3.  Compared to before the change, did hyperemia occur 
after administering the current eye drops?
  (1) hyperemia occurred (2) same (3) hyperemia did not 
occur
4.  When compared to before the change, do your eyes feel 
dry?
(1) felt dryness (2) same (3) did not feel dry
5.  Which eye drops do you prefer?
(1) former eye drops (2) neither (3) current eye drops
6.  What is the reason for your answer to question 5?
  (1) administration frequency (2) administration comfort 
(3) dryness (4) other.
Adverse reactions were examined at every check-up after 
the treatment change. For all cases, a P value of ,0.05 was 
considered statistically significant. The study was reviewed 
and approved by the institutional review board of Inouye Eye 
Hospital at all participating sites. All participating subjects 
provided written informed consent prior to participation and 
the study was conducted in full compliance with all tenants 
of the Declaration of Helsinki.
Results
IOP was 15.5 ± 2.7 mmHg at 1 month after the change, 
15.3 ± 3.6 mmHg at 3 months after the change, and 
15.8 ± 3.2 mmHg at 6 months after the change; none of these 
values were significantly different compared to IOP before the 
change (15.7 ± 2.9 mmHg) (P = 0.191) (  Figure 1). The alterna-
tion at 1 month, 3 months, and 6 months after the change to 
travoprost 0.004%/timolol maleate 0.5% fixed combination 
eye drops is shown in Table 1. Among   questionnaire results, 
before the treatment change, 27 (64.3%) patients responded 
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that they “did not forget to administer eye drops,” four (9.5%) 
patients “forgot to administer once,” two (4.8%) patients 
“forgot to administer more than four times,” nine (21.4%) 
patients did not answer (Figure 2). At 1 month after the change, 
questionnaire results included 30 cases (71.4%) of “did not 
forget to administer eye drops,” four cases (9.5%) of “forgot 
one time,” and eight patients (19.0%) did not answer. Among 
the six patients who answered “forgot to administer” before 
the treatment change, four (66.7%) answered “did not forget 
to administer” and two (33.3%) answered “forgot one time” 
at 1 month after the change. The “did not forget to administer” 
group significantly increased after the change compared with 
that before the change (P , 0.05). Table 2 shows stinging, 
hyperemia, and dryness before and after treatment. In response 
to “which eye drops do you prefer,” five patients (11.9%) 
answered “former eye drops,” 23 (54.8%) answered “current 
eye drops,” 10 (23.8%) answered “neither,” and four patients 
(9.5%) did not answer. The reasons for preferring the current 
eye drops included “administration frequency” in 21 cases, 
“hyperemia lessened” in one case, and “medication expense 
became cheaper” in one case. Reasons for   preferring the 
eye drops before the change included “itchiness increased” 
in three cases and “frequent administration is more effective” 
in two cases.
Thirteen patients (30.2%) discontinued the new treat-
ment protocol within 6 months of the change. One patient 
stopped coming to the hospital, and in five patients, treat-
ment was changed back to travoprost 0.004% and timolol 
maleate 0.5% eye drops because the IOP-decreasing effect 
was   insufficient. Adverse reactions appeared in seven cases 
(16.3%) and included two cases of uneasy feeling, one case 
of contact dermatitis, one case of iritis onset, one case of 
blurred vision, one case of itchiness, and one case of ocular 
pain. Adverse reactions that appeared in the local part of the 
eye disappeared in all cases when treatment was changed 
back to prostaglandin analogs and β-blockers.
Discussion
Administration protocol for travoprost 0.004%/timolol maleate 
0.5% fixed combination eye drops was once a day, whereas 
the protocol for timolol maleate 0.5% eye drops included 
twice-a-day administration. Therefore, a potential reduction 
in IOP-decreasing efficacy was a major concern in this study. 
Schuman et al have reported the IOP-decreasing efficacy and 
safety of travoprost 0.004%/timolol maleate 0.5% fixed com-
bination eye drop monotherapy and those of concomitantly 
used travoprost 0.004% eye drops and timolol maleate 0.5% 
eye drops.6 This randomized, double-masked study involved 
administration of travoprost 0.004%/timolol maleate 0.5% 
fixed combination eye drops (155 cases) or travoprost 0.004% 
20.0
(mmHg) N.S.
IOP
18.0
16.0
14.0
12.0
10.0
8.0
6.0
4.0
2.0
0.0
Before
the change
(n = 43)
1 month after
the change
(n = 43)
3 months after
the change
(n = 36)
6 months after
the change
(n = 30)
Figure 1 IOP before and after changing to travoprost 0.004%/timolol maleate 0.5% 
fixed combination eye drops.
Abbreviation: IOP, intraocular pressure; N.S., not significant.
Table 1   The  alternation  in  intraocular  pressure  at  1  month,   
3 months, and 6 months after the change to travoprost 0.004%/
timolol maleate 0.5% fixed combination eye drops
1 month after  
the change  
(n = 43)
3 months after  
the change  
(n = 36)
6 months after   
the change  
(n = 30)
Cases
Decreased by more  
than 2 mmHg
5 (11.6%) 9 (25.0%) 5 (16.7%)
Within 1 mmHg 35 (81.4%) 18 (50.0%) 16 (53.3%)
Increased by more  
than 2 mmHg
3 (7.0%) 9 (25.0%) 9 (30.0%)
Eye drops before
treatment change
Duo Trav®
N.S.
Forgot eye
drops more
than 4 times,
2 cases, 4.8%
Forgot eye
drops once,
4 cases, 9.5%
Forgot eye
drops once,
4 cases, 9.5%
Didn’t forget
 eye drops,
 27 cases,
64.3%
Didn’t forget
 eye drops,
 30 cases,
71.4%
No response,
8 cases,
19.0%
No response,
9 cases,
21.4%
Figure 2 Results from the questionnaire on drug regimen adherence rates.
Abbreviation: N.S., not significant.
Table 2   The  results  from  the  questionnaire  on  stinging, 
hyperemia, and dryness before and after changing treatment
Stinging Hyperemia Dryness
Cases
Yes 8 (19.0%) 4 (9.5%) 3 (7.1%)
Same 18 (42.9%) 16 (38.1%) 31 (73.8%)
no 16 (38.1%) 21 (50.0%) 5 (11.9%)
no answer – 1 (2.4%) 3 (7.1%)
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
233
Ocular treatment regimen: travoprost/timolol maleate eye dropsClinical Ophthalmology 2012:6
with timolol 0.5% maleate eye drops (142 cases) for patients 
who were diagnosed with POAG or ocular hypertension. The 
range of IOP decrease was 7.3–8.3 mmHg in the group using 
travoprost 0.004%/timolol maleate 0.5% fixed combination 
eye drops and 6.8–8.5 mmHg in the group concomitantly 
using travoprost 0.004% eye drops with timolol maleate 0.5% 
eye drops; these values were not significantly different. The 
frequency of hyperemia appearance was significantly less in 
the travoprost 0.004%/timolol maleate 0.5% fixed combina-
tion eye drop group (P , 0.05). Hughes et al administered 
travoprost 0.004%/timolol maleate 0.5% fixed combination 
eye drops (151 cases) and travoprost 0.004% eye drops with 
timolol maleate 0.5% eye drops (142 cases) for patients who 
were diagnosed with POAG or ocular hypertension in a ran-
domized, double-masked study.7 The range of IOP decrease 
was 7.4–8.7 mmHg in the group using travoprost 0.004%/
timolol maleate 0.5% fixed combination eye drops and 
8.5–9.0 mmHg in the group concomitantly using travoprost 
0.004% eye drops with timolol maleate 0.5% eye drops; these 
values were not significantly different. In these past studies6,7 
there was no significant difference in the IOP-decreasing 
efficacy of travoprost 0.004%/timolol maleate 0.5% fixed 
combination eye drops and travoprost 0.004% eye drops and 
timolol maleate 0.5% eye drops concomitantly used.
The IOP-decreasing effects of travoprost 0.004%/timolol 
maleate 0.5% fixed combination eye drops after changing the 
treatment regimen from prostaglandin analogs and timolol 
maleate 0.5% eye drops have been previously reported.2–5 
Rhee et al examined and assessed the change in IOP at 8 am, 
10 am, 4 pm, and 8 pm for 3 months after the treatment regi-
men for 73 patients who were diagnosed with POAG, exfolia-
tion glaucoma, ocular hypertension, or pigmentary glaucoma.2 
IOP was 14.4–15.4 mmHg when latanoprost 0.005% eye 
drops were used concomitantly with timolol maleate 0.5% 
eye drops and 14.7–15.5 mmHg 3 months after the change; 
these values were not significantly different. Arend and Raber 
assessed IOP 4–6 weeks after treatment change for 528 
patients who were diagnosed with POAG, exfoliation glau-
coma, pigmentary glaucoma, primary angle closure glaucoma, 
or ocular hypertension.3 Among 139 patients concomitantly 
using latanoprost 0.005% eye drops with timolol maleate 0.5% 
eye drops, IOP showed a significant decrease between the 
values before (19.1 ± 3.8 mmHg) and after (16.9 ± 3.4 mmHg) 
the change. Among 339 patients concomitantly using tra-
voprost 0.004% eye drops with timolol maleate 0.5% eye 
drops, IOP showed a significant decrease between the values 
before (17.8 ± 3.6 mmHg) and after (16.7 ± 3.3 mmHg) 
treatment change. Among 50 patients concomitantly using 
bimatoprost 0.03% eye drops with timolol maleate 0.5% eye 
drops, IOP showed a significant decrease between the values 
before (18.2 ± 4.1 mmHg) and after (16.8 ± 4.0 mmHg) 
treatment change. IOP decreasing range was 1.1–2.2 mmHg. 
Rossi et al evaluated IOP at 1 and 6 months after treatment 
change in 309 patients who were diagnosed with POAG or 
ocular hypertension.4 Among patients concomitantly using 
latanoprost 0.005% eye drops with timolol maleate 0.5% eye 
drops, IOP significantly decreased from 18.3 ± 2.9 mmHg 
to 16.6 ± 2.7 mmHg at 1 month after treatment change and 
16.3 ± 2.5 mmHg at 6 months after the change. Scherzer et al 
evaluated IOP 8 weeks after treatment change in 105 patients 
who were diagnosed with POAG or ocular hypertension.5 IOP 
was 16.4 ± 2.8 mmHg at 8 weeks after the treatment change, 
which was not significantly different when compared with 
the IOP in patients concomitantly using bimatoprost 0.03% 
eye drops with timolol maleate 0.5% (20.7 ± 1.2 mmHg). 
Because of the change in treatment, in some studies, IOP 
did not change2,5 and in other studies, it decreased.3,4 In the 
present study, there was no change in IOP after treatment 
change. However, because we did not set up a washout period, 
it is possible that the previous medication was still having an 
effect after the treatment change.
Adverse reactions previously reported for travoprost 
0.004%/timolol maleate 0.5% fixed combination eye drops 
include hyperemia, irritation, itchiness, foreign body sensa-
tion, photophobia, keratitis, blurred vision, allergic reaction, 
and conjunctivitis.2–8 There have been no reports of serious 
adverse reactions,2–8 as was also observed in the present study. 
In this questionnaire, 19.0% of patients felt irritation, 7.1% 
of patients felt dryness, and 9.5% of patients had hyperemia; 
therefore, it is necessary to explain the possibility of adverse 
reactions to the patients prior to changing treatment proto-
cols. In the present study, the eye drops were discontinued 
because adverse reactions appeared in seven cases (16.3%) 
and IOP decrease was inefficient in five cases. The frequency 
of discontinuation was higher in the present study than in past 
reports, which included values of 0%,2 1.0%,5 and 5.1%.4 In 
previous studies, the reasons for discontinuation included 
hyperemia,4,5 pruritus,4 periocular pigmentation,4 burning,4 
dyspnea,4 and allergic reaction,5 which were nearly identical 
to those in the present study.
Dunker et al administered a questionnaire regarding 
treatment protocol adherence for 1052 patients using either 
monotherapy or combination fixed therapy with latanoprost 
0.005%/timolol maleate 0.5% fixed combination eye drops.9 
For “How often does it happen that you forget to use your 
eye drops?” the frequency of the answer “often or almost 
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always” significantly decreased after the change (2%) com-
pared to that before the change (11%). For “Would you like 
to continue with your present eye-drops?” the frequency of 
the answer “probably or definitely” significantly increased 
after the change (92%) compared to that before the change 
(38%). Among cases in which latanoprost 0.005% eye drops 
and timolol maleate 0.5% were used concomitantly, we also 
compared IOP and protocol adherence before and after treat-
ment change to latanoprost 0.005%/timolol maleate 0.5% 
fixed combination eye drops, using subjective judgment 
by a questionnaire.10 There was no change in IOP between 
the values observed before and after the treatment change 
and the frequency of forgetting eye drop administration 
significantly decreased; moreover, 82.1% of the patients 
preferred the latanoprost 0.005%/timolol maleate 0.5% fixed 
combination eye drops. In the present study, the frequency of 
forgetting eye drop administration significantly decreased; 
furthermore, 54.8% of the patients preferred the travoprost 
0.004%/timolol maleate 0.5% fixed combination eye drops. 
However, because the evaluation of adherence was done by 
a questionnaire survey, there is a problem with reliability. If 
electronic adherence measurements were used, the reliability 
might have improved but we did not use these in the present 
study. Moreover, in a medication switching study (as the pres-
ent study), there is the possibility that adherence will improve. 
The results of the present study and those of previous stud-
ies9,10 indicate that fixed combination eye drops are mostly 
preferred to concomitant therapy, as shown by an increase 
in treatment protocol adherence. However, in the present 
study, IOP increased by more than 2 mmHg after treatment 
change in three cases (7.0%) at 1 month after the change, in 
nine cases (25.0%) at 3 months after the change, and in nine 
cases (30.0%) at 6 months after the change. In these cases, 
the administration frequency of timolol maleate eye drops 
was changed from twice a day to once a day, because this 
was considered to decrease IOP.
In conclusion, Japanese patients diagnosed with POAG 
who had been formerly treated with two types of eye drops 
(prostaglandin analogs and β-blockers) and were   subsequently 
treated with one type of eye drop (travoprost 0.004%/
timolol maleate 0.5% fixed combination) experienced an 
increase in treatment administration adherence with main-
tenance of IOP. However, in some cases, adverse reactions, 
such as stimulation, appeared and IOP increased. Therefore, 
patients in whom treatment is changed to fixed, combination 
eye drops should be carefully followed up.
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